An ongoing clinical trial (NCT03590574) is currently investigating the safety and efficacy of a TRBC1-targeting CAR-T therapy named AUTO4 in patients with TRBC1+ T-cell non-Hodgkin lymphoma (T-NHL), PTCL, angioimmunoblastic T-cell lymphoma (AITL), and ALCL. The gene discussed is TRBC1; the disease is anaplastic large cell lymphoma.